Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT) - Wikidata - wikimedia - TriplyDB

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

http://www.wikidata.org/entity/Q38795816

about

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.Design and engineering of deimmunized biotherapeutics.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment.

P2860

Q34804520-33C921F1-3B94-4039-A963-3E62BBF25054 Q35915376-4ACD1D8A-329C-430F-A378-93ABA8FD1524 Q36837402-9CDF3070-9645-4645-AB58-19DFEFD30C1F Q37376557-EBDDEFA9-DB3E-4C0D-858B-3AC44691FD1C Q38158247-CDADEC32-C1A2-4D4E-BCDC-0E903020A739 Q38870681-997DC512-6A8D-46E7-B4E0-03E7EF0895DF Q38979784-959E7BC7-A2D2-4FC0-BC42-9DA39A8B7E17 Q53689115-AC68A730-E72A-42F5-9998-62AA68AEEE42

P2860

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

http://www.wikidata.org/entity/Q38795816

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Modifying an immunogenic epito ...... enzyme prodrug therapy (ADEPT)

@en

type

label

Modifying an immunogenic epito ...... enzyme prodrug therapy (ADEPT)

@en

prefLabel

Modifying an immunogenic epito ...... enzyme prodrug therapy (ADEPT)

@en

P1433

Q38795816-E1F85588-67E1-4A23-A9E8-B2C21E90DC26

P1476

Q38795816-93D60DF7-8743-4A89-BD82-EB63D3D7869A

P2093

Q38795816-00ECD8BB-C615-4D25-99ED-BB5FFFEFD084

Q38795816-01ED0700-0634-4A03-8888-DF8B5872A2E4

Q38795816-3F12C2C4-9CAF-40E9-A319-BEDC14760CD1

Q38795816-404A123D-3251-42D9-BAD2-CCE33AA6F69F

Q38795816-5EB7FAB1-80D5-46F2-B8F3-4406F9220303

Q38795816-6E83D5AD-2718-4710-A1CE-5363E5CEB329

Q38795816-99966614-BB52-4A16-A41B-0CFB353BCF30

Q38795816-EFD72BA6-BB40-4DB8-9B31-CE05B25021AF

P2860

Q38795816-040596B5-7CDA-402A-B003-A4EDBE537013

Q38795816-04258057-AB2A-4FB7-8E45-E00C57B8BBE5

Q38795816-091201B5-7FC2-4983-997E-96A812DB0DFC

Q38795816-1187942E-0151-45C7-B243-67CFD32A92B2

Q38795816-274731E2-ADED-45C2-9512-CA0339210E5B

Q38795816-2E6C31E5-8A6C-4086-8CBC-A19C49CBFCF7

Q38795816-35EDB24F-47FE-46E9-89F5-4432816D7844

Q38795816-3FF7693F-0022-4101-BB08-3F76547079D1

Q38795816-5A6B3223-77BE-451F-B5C1-52B25DAD6BC2

Q38795816-66470C43-AC9D-4E7D-8CE6-8044D715A099

P2888

Q38795816-C443E902-DD19-407C-AA4E-31428779E612

P304

Q38795816-E6198351-30AF-4EA1-981B-6B8FE9F59242

P31

Q38795816-3F16222D-22A6-48E3-BCDF-5183CD4DF1D1

P356

Q38795816-AAB449EF-79BD-43E3-9C61-57EBA2167FE6

P407

Q38795816-CB655699-B512-4B33-B2D1-F629F13D67C0

P433

Q38795816-11EAE9A0-40E1-48E2-B6C4-F9337B1979ED

P478

Q38795816-22111063-A45C-4036-954A-B515A0909E4A

P50

Q38795816-50F0E60B-D4BF-478C-9BB1-BFBFD14551F3

P577

Q38795816-FA270565-3CC1-4E5E-9DFF-DA2C43F58560

P5875

Q38795816-8A6D8209-5F7A-479B-9B4C-67FA78D4AE47

P6179

Q38795816-19FA6077-1052-48AB-9349-EA416DC9FABA

P698

Q38795816-67EA6AF5-B643-40BC-82F3-5B15C16EF1A1

P932

Q38795816-41287AB5-69A9-4E5F-B1AB-6D754769BC11

P356

P1433

British Journal of Cancer

P1476

Modifying an immunogenic epito ...... enzyme prodrug therapy (ADEPT)

@en

P2093

A Mayer

http://www.w3.org/2001/XMLSchema#string

B Tolner

http://www.w3.org/2001/XMLSchema#string

D Purdy

http://www.w3.org/2001/XMLSchema#string

G Tharakan

http://www.w3.org/2001/XMLSchema#string

K A Chester

http://www.w3.org/2001/XMLSchema#string

P Amlot

http://www.w3.org/2001/XMLSchema#string

R H J Begent

http://www.w3.org/2001/XMLSchema#string

S K Sharma

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

MOLMOL: a program for display and analysis of macromolecular structures

Engineered antibodies

Improving the efficacy of antibody-based cancer therapies

The danger model: a renewed sense of self

Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.

Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.

Renaissance of cancer therapeutic antibodies.

Minimizing the immunogenicity of protein therapeutics.

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

P2888

P304

2402-2410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601888

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8544603

http://www.w3.org/2001/XMLSchema#string

P6179

1034078410

http://www.w3.org/2001/XMLSchema#string

P698

15162148

http://www.w3.org/2001/XMLSchema#string

P932

2409521

http://www.w3.org/2001/XMLSchema#string